Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.42 |
| ▸ | FAP | Q12884 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.41 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 3/20 | 0.38 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29101143 | 1.00 | OPRM1 (0.42) | OPRM1DPP4PREPFAPDPP8 | |
| SCHEMBL28725265 | 1.00 | OPRM1 (0.42) | OPRM1DPP4PREPFAPDPP8 | |
| SCHEMBL30139053 | 0.95 | CAPN1 (0.42) | OPRM1DPP4PREPFAPDPP8 | |
| SCHEMBL29680076 | 0.90 | OPRM1 (0.45) | OPRM1ITGB1ITGA5F2CAPN1 | |
| SCHEMBL29467320 | 0.89 | CAPN1 (0.48) | OPRM1DPP4PREPFAPDPP8 | |
| SCHEMBL30028652 | 0.89 | ITGB1 (0.43) | OPRM1PREPFAPITGB1ITGA5 | |
| SCHEMBL30825687 | 0.88 | OPRM1 (0.46) | OPRM1DPP4PREPFAPDPP8 | |
| SCHEMBL30862236 | 0.88 | DPP4 (0.41) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL28943531 | 0.87 | DPP4 (0.40) | DPP4PREPFAPDPP8DPP9 | |
| SCHEMBL26389253 | 0.87 | DPP4 (0.40) | OPRM1DPP4PREPFAPDPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339489-A1 | COMPOSITION FOR SUPPRESSING HAIR LOSS OR PROMOTING HAIR GROWTH CONTAINING PEPTIDE | AMOREPACIFIC CORPORATION (KR) | 2025-11-06 | — | — | US | claimed |
| US-20250212912-A1 | COLLAGEN PEPTIDE COMPOSITIONS FROM FISH SKINS AND SCALES AND METHODS FOR PRODUCING SAME | THAI UNION GROUP PUBLIC COMPANY LIMITED (TH) | 2025-07-03 | — | — | US | claimed |
| CN-114377111-B | Pharmaceutical composition for resolving phlegm and relieving cough | 上海市肺科医院 | 2023-09-12 | — | — | CN | claimed |
| CN-114315960-B | Modified peptide, and cosmetic composition or medicinal composition and application thereof | 深圳市维琪医药研发有限公司 | 2022-10-14 | — | — | CN | claimed |
| CN-115181173-A | Preparation method of Tirzepatide | 深圳市健元医药科技有限公司 | 2022-10-14 | — | — | CN | claimed |
| US-20220127326-A1 | Targeted Therapeutic Lysosomal Enzyme Fusion Proteins and Uses Thereof | BIOMARIN PHARMACEUTICAL INC. | 2022-04-28 | — | — | US | claimed |
| CN-114377111-A | Pharmaceutical composition for eliminating phlegm and relieving cough | 上海市肺科医院 | 2022-04-22 | — | — | CN | claimed |
| CN-114315960-A | Modified peptide, and cosmetic composition or medicinal composition and application thereof | 深圳市维琪医药研发有限公司 | 2022-04-12 | — | — | CN | claimed |
| EP-4743102-A1 | COLLAGEN PEPTIDE COMPOSITION AND USE THEREOF IN AMELIORATING NEUROLOGICAL CONDITIONS AND FIBROSIS | Rousselot BV (BE) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026087731-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMINO ACID COMPOSITION IN PURIFIED HYALURONIC ACID | INTIBIO BV (BE) | 2026-04-30 | — | — | WO | disclosed |
| US-20250388644-A1 | TARGETED THERAPEUTIC LYSOSOMAL ENZYME FUSION PROTEINS AND USES THEREOF | BIOMARIN PHARM INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12478082-B2 | Uridine diphosphate-dependent glycosyltransferase enzyme | MANUS BIO INC. (US) | 2025-11-25 | — | — | US | disclosed |
| US-20250339489-A1 | COMPOSITION FOR SUPPRESSING HAIR LOSS OR PROMOTING HAIR GROWTH CONTAINING PEPTIDE | AMOREPACIFIC CORPORATION (KR) | 2025-11-06 | — | — | US | disclosed |
| EP-3565834-B1 | ANTIBODY FRAGMENTS FOR THE TREATMENT OF BIOFILM-RELATED DISORDERS | THE RES INSTITUTE AT NATIONWIDE CHILDRENS HOSPITAL (US) | 2025-10-22 | — | — | EP | disclosed |
| CN-114377111-A | Pharmaceutical composition for eliminating phlegm and relieving cough | 上海市肺科医院 | 2022-04-22 | — | — | CN | disclosed |
| CN-114377111-A | Pharmaceutical composition for eliminating phlegm and relieving cough | 上海市肺科医院 | 2022-04-22 | — | — | CN | disclosed |
| CN-114315960-A | Modified peptide, and cosmetic composition or medicinal composition and application thereof | 深圳市维琪医药研发有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3365027-B1 | HU SPECIFIC ANTIBODIES AND THEIR USE IN INHIBITING BIOFILM | RES INST NATIONWIDE CHILDRENS HOSPITAL (US) | 2022-03-30 | — | — | EP | disclosed |
| US-11274144-B2 | Compositions and methods for the removal of biofilms | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL (US) | 2022-03-15 | — | — | US | disclosed |
| CN-103665170-A | Peptide therapeutic conjugates and uses thereof | ANGIOCHEM INC | 2014-03-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388644-A1 | TARGETED THERAPEUTIC LYSOSOMAL ENZYME FUSION PROTEINS AND USES THEREOF | GAA, IDE, IDUA | OPRM1 4582/4885DPP4 490/4885PREP 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.